-+ 0.00%
-+ 0.00%
-+ 0.00%

Entrada Q1 net loss widens to $39.7 million; collaboration revenue drops to $0.9 million

PUBT·05/07/2026 11:19:01
Listen to the news
Entrada Q1 net loss widens to $39.7 million; collaboration revenue drops to $0.9 million
  • Entrada Therapeutics posted a Q1 net loss that widened to USD 39.7 million, or USD 0.95 per share, from USD 17.3 million, or USD 0.42 per share, a year earlier.
  • Collaboration revenue fell to USD 875,000 from USD 20.6 million, on substantial completion of VX-670 collaboration research-plan activities in Q1 2025.
  • R&D expenses rose to USD 33.1 million from USD 32.1 million, while G&A spending edged down to USD 10.1 million from USD 10.3 million.
  • Cash, cash equivalents and marketable securities declined to USD 254.9 million as of March 31 from USD 295.7 million at year-end 2025; cash runway expected into Q3 2027.
  • Positive ELEVATE-44-201 Cohort 1 topline data for ENTR-601-44 showed favorable safety and tolerability with statistically significant improvement in Time to Rise velocity; ELEVATE-45-201 Cohort 1 data expected in mid-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070710PRIMZONEFULLFEED9714644) on May 07, 2026, and is solely responsible for the information contained therein.